Harrow, Inc. Sale Leaseback Transaction, Net Proceeds, Investing Activities
Harrow, Inc. (HROW) reported Sale Leaseback Transaction, Net Proceeds, Investing Activities of $841.00 thousand for the 9-month period ending 2016-09-30, per its 10-Q filed 2016-11-14.
Discontinued › Cash Flow › Investing Activities
us-gaap:SaleLeasebackTransactionNetProceedsInvestingActivities · last filed 2016-11-14
- Harrow, Inc. sale leaseback transaction, net proceeds, investing activities for the quarter ending 2016-09-30 was -$1.16M.
| Period end | Sale Leaseback Transaction, Net Proceeds, Investing Activities 3 month | Sale Leaseback Transaction, Net Proceeds, Investing Activities 6 month | Sale Leaseback Transaction, Net Proceeds, Investing Activities 9 month |
|---|---|---|---|
| 2016-09-30 | -$1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $841.00K 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $2.00M 10-Q · filed 2016-08-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |